A research-focused summary of recently published literature. For research and educational purposes only. The compounds discussed are supplied strictly for in-vitro research and laboratory use and are not intended for human consumption.
The last two years have been unusually active for peptide and incretin research, from large late-stage clinical programs for the GLP-1 class to a steady accumulation of preclinical work on regenerative and mitochondrial peptides. This roundup collects several of the more notable recent publications on compounds in our catalog, with primary and peer-reviewed sources cited throughout so you can read the underlying work directly.
BPC-157: A Growing Preclinical Evidence Base in Musculoskeletal Models
BPC-157 (stable gastric pentadecapeptide) continues to be studied primarily in animal models of tendon, ligament, and muscle injury. A 2025 systematic review in Orthopaedic Journal of Sports Medicine synthesized 36 studies published between 1993 and 2024, describing consistent improvements in biomechanical healing outcomes - for example, greater failure load and tissue stiffness in rat Achilles-tendon rupture models within roughly 10-14 days versus untreated controls (Vasireddi et al., 2025).
Mechanistically, the literature attributes these effects to accelerated angiogenesis (including upregulation of VEGFR2), increased type I collagen production, and activation of the FAK-paxillin and Src-caveolin-1-eNOS pathways. Earlier work also documented dose- and time-dependent upregulation of the growth-hormone receptor in tendon fibroblasts at both the mRNA and protein levels.
The key caveat, and an important one for researchers: the evidence base remains overwhelmingly preclinical. As of 2024 only a single pilot human study - an intravenous tolerance evaluation - had been published, so translational conclusions are premature.
GHK-Cu: Copper-Peptide Gene Modulation and a New Clinical Trial
GHK-Cu, a copper-binding tripeptide, is studied for its role in tissue remodeling and skin regeneration. Bioinformatic analyses have suggested it can influence the expression of thousands of human genes, and in-vitro work shows upregulation of extracellular-matrix genes such as COL1A1, elastin, and decorin alongside suppression of certain inflammatory signals.
Notably, GHK-Cu research is beginning to move toward controlled human evaluation: a topical GHK-Cu gel is the subject of a registered clinical trial (ClinicalTrials.gov NCT07437586) assessing wound healing in standardized punch-biopsy wounds against a vehicle control. That kind of registered, controlled design is what the field needs more of.
MOTS-c: The Exercise-Mimetic Mitochondrial Peptide
MOTS-c is a 16-amino-acid peptide encoded not by nuclear DNA but by the mitochondrial 12S rRNA gene. It is induced by exercise and metabolic stress, translocates to the nucleus, and appears to act largely through the folate-AICAR-AMPK axis to influence energy metabolism and stress adaptation - while its expression tends to decline with age.
Recent work has extended the metabolic story: a 2025 study in Frontiers in Physiology reported that MOTS-c helped restore mitochondrial respiration in a type-2-diabetic heart model, and other 2024-2025 preclinical studies have examined its effects on muscle atrophy and diabetic liver fibrosis. Human evaluation remains early.
Retatrutide: The Triple Agonist Posting the Largest Weight-Loss Figures Yet
Retatrutide is a first-in-class triple-hormone-receptor agonist acting at the GIP, GLP-1, and glucagon receptors. Its Phase 2 obesity trial, published in the New England Journal of Medicine (Jastreboff et al., 2023), reported dose-dependent weight reduction that drew considerable attention.
In 2025 the Phase 3 TRIUMPH program began reading out. TRIUMPH-1 met its primary and key secondary endpoints across all doses, and reported figures included a large share of participants dropping below the obesity BMI threshold; later readouts described average reductions approaching or exceeding roughly 28-30% of body weight at extended time points. Several additional TRIUMPH trials - spanning type 2 diabetes, sleep apnea, MASLD, and cardiovascular outcomes - are expected to report through 2026, so this is a fast-moving area worth tracking against the primary publications as they appear.
Orforglipron: The First Oral, Non-Peptide GLP-1 Agonist to Clear Phase 3
Orforglipron is distinct from the injectable peptide agonists: it is an oral, non-peptide, small-molecule GLP-1 receptor agonist - a GLP-1-only agent, not a dual or triple agonist, and unrelated to tirzepatide. Because it is a small molecule, it does not require an injectable format, an absorption enhancer, or the fasting-and-water restrictions associated with oral peptide formulations.
Its late-stage data arrived in 2025. The ACHIEVE program evaluated orforglipron in early type 2 diabetes, with results published in the New England Journal of Medicine (ACHIEVE-1; PMID 40544435), while the ATTAIN obesity program reported meaningful weight reduction - on the order of about 11% at 72 weeks for the highest dose in ATTAIN-1. As an oral small molecule, it represents a genuinely different pharmacological approach within the GLP-1 landscape.
References
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Orthopaedic Journal of Sports Medicine, 2025.
- Tendon, Ligament, and Muscle Injury: Stable Gastric Pentadecapeptide BPC 157 - A Review. Pharmaceuticals (MDPI), 2025.
- Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts.
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review. Int J Med Sci, 2025.
- Topical GHK-Cu Gel for Acute Skin Wound Healing. ClinicalTrials.gov NCT07437586.
- Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 2023.
- Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Frontiers in Physiology, 2025.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med, 2023.
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH). 2025.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med, 2025. PMID 40544435.
This article summarizes publicly available research for educational purposes and does not constitute medical advice, a therapeutic claim, or a recommendation for human use. Products referenced are sold for laboratory research use only.